Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
71 results about "Nociception" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Nociception (also nocioception or nociperception, from Latin nocere 'to harm or hurt') is the sensory nervous system's response to certain harmful or potentially harmful stimuli. In nociception, intense chemical (e.g., chili powder in the eyes), mechanical (e.g., cutting, crushing), or thermal (heat and cold) stimulation of sensory nerve cells called nociceptors produces a signal that travels along a chain of nerve fibers via the spinal cord to the brain. Nociception triggers a variety of physiological and behavioral responses and usually results in a subjective experience of pain in sentient beings.
Determination of the anesthetic state of a patient
ActiveUS20060217628A1Limited stateQuality improvementElectroencephalographyElectrocardiographyBalanced AnesthesiaHypnosis
The invention relates to the determination of the anesthetic state of a patient. In order to achieve a mechanism that enables establishment and maintenance of balanced anesthesia, values are established for a set of diagnostic indices. The set includes at least two diagnostic indices of which a first diagnostic index is indicative of the level of hypnosis and a second diagnostic index of the level of nociception in the patient. The combination of the at least two index values obtained is employed for indicating the anesthetic state of the patient. The combination of the at least two index values may further be employed to control the administration of drugs to the patient.
Owner:GENERAL ELECTRIC CO
Determination of the clinical state of a subject
ActiveUS20060217614A1Strong specificityAutomatic controlElectrocardiographyEvaluation of blood vesselsMedicineIndex score
The invention relates to the determination of the clinical state of a subject. In order to bring about an uncomplicated method for monitoring the clinical state of a subject and for accomplishing a diagnostic scale, such as a nociception scale, on which a certain reading corresponds to the same level for all patients, a normalization transform is applied to a measurement signal containing physiological data obtained from a patient, whereby a normalized measurement signal having a predetermined value range is obtained. The normalization transform is dependent on predetermined history data, such as previous signal data of said measurement signal. A diagnostic index dependent on the normalized measurement signal is then formed, the diagnostic index serving as a measure of the clinical state of the patient. The diagnostic index may be formed based on one or more normalized measurement signals.
Owner:GENERAL ELECTRIC CO
Genome editing of sensory-related genes in animals
The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with nociception or taste disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.
Owner:SIGMA ALDRICH CO LLC
System and method for detecting pain and its components using magnetic resonance spectroscopy
InactiveUS7676254B2Diagnostic recording/measuringMeasurements using NMR imaging systemsMetaboliteAssessing Pain
Owner:SYDNEY UNIV OF +2
Benzimidazole derivatives
InactiveUS7125877B2High selectivityExcellent antagonismGroup 4/14 element organic compoundsBiocideBenzimidazole derivativeHypotension shock
This invention provides compounds which are represented by a general formula [I][in which X stands for hydrogen or halogen; B stands for halogen, cyano or optionally fluorine-substituted lower alkyl; D stands for a 3–10 membered aliphatic nitrogen-containing heterocyclic group; R3, R4 and R5 may be same or different, and each stands for hydrogen, lower alkyl optionally having substituent group(s) and the like; and a is 0 or 1]. These compounds exhibit high affinity to nociceptin receptors and whereby inhibit actions of nociceptin, and are useful as an analgesic, antiobestic, agent for ameliorating brain function, treating agents for Alzheimer's disease and dementia, and therapeutic agents for schizophrenia, neurodegenerative diseases, depression, diabetes insipidus, polyuria, hypotension and the like.
Owner:MSD KK
Determination of the anesthetic state of a patient
ActiveUS7925338B2Quality improvementElectroencephalographyElectrocardiographyBalanced AnesthesiaHypnosis
The invention relates to the determination of the anesthetic state of a patient. In order to achieve a mechanism that enables establishment and maintenance of balanced anesthesia, values are established for a set of diagnostic indices. The set includes at least two diagnostic indices of which a first diagnostic index is indicative of the level of hypnosis and a second diagnostic index of the level of nociception in the patient. The combination of the at least two index values obtained is employed for indicating the anesthetic state of the patient. The combination of the at least two index values may further be employed to control the administration of drugs to the patient.
Owner:GENERAL ELECTRIC CO
Modulation of activity of proneurotrophins
The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps10p-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and / or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and / or nociception in an individual.
Owner:H LUNDBECK AS
Neuropeptide release assay for sodium channels
ActiveUS8486647B2High activityReduced activityCell receptors/surface-antigens/surface-determinantsSugar derivativesDiseaseBiological activation
Methods and compositions for using genetically modified non-human animals are provided, wherein the genetic modification comprises a humanization of the one or more extracellular pore loops of a NaV1.7 channel protein or a complete humanization of an endogenous NaV1.7 gene. Methods for using isolated DRG cultures from genetically modified non-human animals are also provided, wherein the isolated DRG express a human or chimeric NaV1.7 protein on the surface, in particular measuring primary nociceptive activation through the release of calcitonin gene-related peptide (CGRP) in isolated DRG in vitro, and wherein the isolated DRG cultures are capable of generating action potentials and communicating through an excitable signal via the expressed human or chimeric NaV1.7 protein the cell surface. In vivo and in vitro methods for characterizing NaV1.7-specific antagonists and evaluation of corresponding therapeutic potential for NaV1.7-mediated disease are also provided.
Owner:REGENERON PHARM INC
Nociceptin analogs
Owner:PURDUE PHARMA LP
Device and method for assessing the level of consciousness, pain and nociception during wakefulness, sedation and general anaesthesia
The present invention disclosed a device and method for assessing in real time the hypnotic and analgesic effect in a subject during wakefulness, sedation and general anaesthesia via drug interactions and physiological signals. In a preferred embodiment of the present invention, the analgesic and hypnotic effect of drug(s) infused in a subject could be accurately assessed in real time through the device and method disclosed in the present invention, comprising steps of receiving data from electroencephalography (EEG) device, receiving data from brain impedance tomography device, obtaining pharmacodynamic and pharmacokinetic parameters of drug(s) infused in the subject, defining initial indices of consciousness and nociception as a function of said EEG and brain impedance tomography data, and generating output of final indices of consciousness and nociception in real time from processing input of EEG, brain tomography and drug interaction data using established mathematical manipulation.
Owner:QUANTIUM MEDICAL
Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation
InactiveUS20100119506A1Improve inflammatory responseModulate inflammatory responseAntipyreticAnalgesicsFactor iiBiological activation
The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.
Owner:BOEHRINGER INGELHEIM PHARMA INC +1
Cns chloride modulation and uses thereof
InactiveUS20070092510A1Decreasing chloride levelModulating activityCompounds screening/testingOrganic active ingredientsUltrasound attenuationChloride transporter
Methods and products for the attenuation or treatment of pain and the reduction of nociception are described. The methods and products are based on the modulation of CNS intracellular chloride levels. The methods and products may also relate to modulation of the activity and / or expression of a chloride transporter, such as the KCC2 potassium-chloride cotransporter. Also described herein are commercial packages and uses based on such modulation. Related methods for identifying or characterizing a compound for the treatment of pain, the reduction of nociception and the diagnosis and prognostication of pain are also described.
Owner:UNIV LAVAL
Triazospiro compounds having nociceptin receptor affinity
Disclosed are compounds of the formula (I)wherein A, R1, R2, R3, R4 and X1 are as disclosed herein. The compounds have affinity for the ORL1 receptor and are useful in the treatment of chronic and acute pain.
Owner:PURDUE PHARMA LP
Treating neuropathic pain with neuropeptide FF receptor 2 agonists
The invention described below relates to the discovery of the neuropeptide FF receptor subtype that mediates acute nociception and chronic neuropathic pain, compounds that selectively interact with this receptor subtype and methods for treating acute pain and chronic neuropathic pain.
Owner:ACADIA PHARMA INC
Treating neuropathic pain with neuropeptide FF receptor 2 agonists
InactiveUS20050136444A1Relieve pain symptomsRelieve symptomsOrganic active ingredientsCompound screeningReceptor subtypeAgonist
The invention described below relates to the discovery of the neuropeptide FF receptor subtype that mediates acute nociception and chronic neuropathic pain, compounds that selectively interact with this receptor subtype and methods for treating acute pain and chronic neuropathic pain.
Owner:ACADIA PHARMA INC
Modulation of activity of proneurotrophins
The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and / or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and / or nociception in an individual.
Owner:H LUNDBECK AS
Triazospiro compounds having nociceptin receptor affinity
InactiveUS20010041711A1Eliminate side effectsBiocideNervous disorderCombinatorial chemistryNociception
Disclosed are compounds of the formula (I) wherein A, R1, R2, R3, R4 and X1 are as disclosed herein. The compounds have affinity for the ORL1 receptor and are useful in the treatment of chronic and acute pain.
Owner:PURDUE PHARMA LP
Antipruritics
The present invention relates to an antipruritic agent comprising a nociceptin antagonist as an active ingredient. The nociceptin antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney dialysis, diabetes, blood disease, liver disease, kidney disease, incretion and metabolic disorder, viscera malignant tumor, hyperthyroidism, autoimmune disease, multiple sclerosis, neurologic disease, psychoneurosis, allergic conjunctivitis, spring catarrh, atopic keratoconjunctivitis, or itching caused by excess use of laxuries and drugs because it has excellent scrtaching behavior suppressing effect, that is, antiitching effect and antipruritic effect.
Owner:NIPPON SHINYAKU CO LTD
Nociceptin analogs
InactiveUS20030013874A1Sufficient time for metabolismHigh yieldBiocideNervous disorderStereochemistryOrganic chemistry
Owner:PURDUE PHARMA LP
Neuropeptide Release Assay For Sodium Channels
Methods and compositions for using genetically modified non-human animals are provided, wherein the genetic modification comprises a humanization of the one or more extracellular pore loops of a NaV1.7 channel protein or a complete humanization of an endogenous NaV1.7 gene. Methods for using isolated DRG cultures from genetically modified non-human animals are also provided, wherein the isolated DRG express a human or chimeric NaV1.7 protein on the surface, in particular measuring primary nociceptive activation through the release of calcitonin gene-related peptide (CGRP) in isolated DRG in vitro, and wherein the isolated DRG cultures are capable of generating action potentials and communicating through an excitable signal via the expressed human or chimeric NaV1.7 protein the cell surface. In vivo and in vitro methods for characterizing NaV1.7-specific antagonists and evaluation of corresponding therapeutic potential for NaV1.7-mediated disease are also provided.
Owner:REGENERON PHARM INC
Non-cytotoxic protein conjugates
ActiveUS20140294797A1Peptide/protein ingredientsAntibody mimetics/scaffoldsADAMTS ProteinsCytotoxicity
The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, β-endorphin, bradykinin, substance P, dynorphin and / or nociceptin.
Owner:IPSEN BIOINNOVATION
Application of nervous excitation damage related polypeptide in preventing, relieving or treating pain
The invention provides an application of a peptide containing an amino acid sequence YEKLLDTEI or functional variants thereof or pharmaceutical composition containing the peptide in preparation of drugs for preventing, relieving or treating pain, particularly nociceptive pain as well as a method for preventing, relieving or treating the pain.
Owner:BIOCELLS BEIJING BIOTECH CO LTD
Nociceptin Analogues and Uses Thereof
InactiveUS20080287478A1Reduce impactGood oral availabilityBiocideNervous disorderPeptideSpiro compound
Owner:ZEALAND PHARM AS
Determination of the clinical state of a subject
ActiveUS8715193B2Strong specificityAutomatic controlElectrocardiographyEvaluation of blood vesselsMedicineIndex score
The invention relates to the determination of the clinical state of a subject. In order to bring about an uncomplicated method for monitoring the clinical state of a subject and for accomplishing a diagnostic scale, such as a nociception scale, on which a certain reading corresponds to the same level for all patients, a normalization transform is applied to a measurement signal containing physiological data obtained from a patient, whereby a normalized measurement signal having a predetermined value range is obtained. The normalization transform is dependent on predetermined history data, such as previous signal data of said measurement signal. A diagnostic index dependent on the normalized measurement signal is then formed, the diagnostic index serving as a measure of the clinical state of the patient. The diagnostic index may be formed based on one or more normalized measurement signals.
Owner:GENERAL ELECTRIC CO
Amide derivatives and nociceptin antagonists
The present invention relates to a compound of the formula [1′] wherein R2 is lower alkyl optionally substituted by hydroxy, amino and the like, ring B is phenyl, thienyl and the like, E is a single bond, —O—, —S— and the like, ring G is aryl, heterocyclic group and the like, R5 is halogen atom, hydroxy, lower alkyl optionally substituted by halogen atom etc., and the like, t is 0 or an integer of 1 to 5, when t is an integer of 2 to 5, each R5 may be the same or different, m is 0 or an integer of 1 to 8, and n is 0 or an integer of 1 to 4, and a nociceptin antagonist containing compound [1′] as an active ingredient. The compound [1′] shows, due to nociceptin antagonistic action, analgesic effect against sharp pain such as postoperative pain and the like. The present invention also relates to the use of certain amide derivative inclusive of compound [1′] as a nociceptin antagonist or analgesic.
Owner:JAPAN TOBACCO INC
Antipruritics
InactiveUS20080103162A1Good curative effectOrganic active ingredientsBiocideAutoimmune conditionNervous system
The present invention relates to an antipruritic agent comprising a nociceptine antagonist as an active ingredient. The nociceptine antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney dialysis, diabetes, blood disease, liver disease, kidney disease, incretion and metabolic disorder, viscera malignant tumor, hyperthyroidism, autoimmune disease, multiple sclerosis, neurologic disease, psychoneurosis, allergic conjunctivitis, spring catarrh, atopic keratoconjunctivitis, or itching caused by excess use of laxuries and drugs because it has excellent scratching behavior suppressing effect, that is, antiitching effect and antipruritic effect.
Owner:OYAMA TATSUYA +1
Modulation of neuroglia-derived BDNF in the treatment and prevention of pain
Owner:HOSPITAL FOR SICK CHILDREN +1
Application of inhibitor SB (Sodium Butyrate) 203580 of p (phosphor) -p38
The invention aims to provide application of an inhibitor SB (Sodium Butyrate) 203580 of p (phosphor)-p38. Activation of phosphor-p38 mediated microglial cells contributes to pain correlated responses of a pain model of BmKI (Biomedical Knowledge Integration); the specific inhibitor SB 203580 of the p-p38 can inhibit the microglial cell and thus relieving the pain correlated responses in the pain model of the BmKI. The invention provides a theoretical basis for pain central sensitization induced by peripheral damages, a study carrier for studying cellular and molecular mechanisms and treatment strategies of nociception and an experimental basis for studying novel drugs for relieving the pain on clinic are provided. The SB 203580 has a prospect of becoming a tool medicine applied in studying correlated pain mechanism of p38 signal path and then has a potential prospect of developing drugs for treating and relieving pathological pain and maintaining corresponding drugs on clinic.
Owner:SHANGHAI UNIV
Pain management in sickle cell anemia
The present invention relates to a method for the management of pain associated with sickle cell disease. In particular, the method comprises administering to a patient in need of such pain management a therapeutically effective amount of a nociceptin (NOP) receptor agonist or an NOP receptor agonist / mu opioid receptor (MOR) partial agonist.
Owner:RGT UNIV OF MINNESOTA +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com